Stalicla ^Company

Stalicla is a biotech company that focuses on precision molecular neuroscience. They have a pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. Stalicla's unique approach addresses a weakness in the drug development process for NDD's and neuropsychiatric disorders. Their technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The DEPI platform has already completed several successful clinical validations. Stalicla will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb. Stalicla is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.